Cognitive Decline in AD
A Cohort Study of Cognitive Decline in Alzheimer Disease
Chinese University of Hong Kong
500 participants
Dec 13, 2018
OBSERVATIONAL
Conditions
Summary
There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors. In addition there may be biomarkers e.g. inflammatory cytokines that can contribute to cognitive decline. The impact of care arrangement and physical activity may also be important. Insulin signaling is impaired in Alzheimer disease (AD). We therefore propose to perform a cohort study of older people with AD. This will be based on an on-going AD registry which was designed to identify genetic biomarkers for AD. Detailed neurocognitive tests and lifestyle information are available. In addition, volumetric MRI brain scans were performed in all AD subjects. The hypothesis is that MRI brain volumes, serum biomarkers, physical activity, physical functioning are independently associated with cognitive decline in older people with AD. The objective is to identify risk factors of accelerated cognitive decline so that preventive measures can be designed to delay dependency in AD.
Eligibility
Inclusion Criteria3
- Sufficient Cantonese competency for cognitive test
- Clinical diagnosis of AD
- FAST test staging 3-5
Exclusion Criteria2
- Subjects who refuse blood taking procedure
- No reliable family caregiver informant (person contact at least once a month)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03946930